Core Viewpoint - The domestic beauty industry in China has reached unprecedented heights, with domestic brands capturing 57.37% of the market share by 2025, marking a significant milestone. However, the industry is now facing new challenges as it transitions from a phase of rapid growth to one focused on capability and efficiency [3][9]. Group 1: Industry Transition - The industry is shifting from "opportunity-driven" to "capability-driven," indicating a maturation phase where brand value and organizational efficiency are becoming critical for sustained growth [4][9]. - The overall market growth has slowed to around 2% annually, leading to increased costs for online traffic and a lack of recovery in offline channels, prompting brands to reassess their strategies [9][10]. - Companies are now focusing on internal efficiency and profit recovery rather than merely expanding their scale, as evidenced by the proactive measures taken by brands like Huaxi Biological and Shanghai Jahwa [10][13]. Group 2: Case Studies of Brand Adjustments - Huaxi Biological faced a significant decline in net profit, over 70% in 2024, due to resource dispersion and cost structure imbalances. In response, the company decided to streamline operations by shutting down non-core brands and focusing on four key brands, leading to a projected profit increase of 54.93% to 83.63% in 2025 [10][12]. - Shanghai Jahwa has also undergone deep adjustments, expecting to turn a profit in 2025 after significant losses in previous years. The company emphasized "four focuses" to ensure competitive pricing and brand strength in key categories [13][15]. Group 3: New Market Entrants and IPOs - New brands like HBN, Banmu Huatian, and Lin Qingxuan are entering the capital market, with HBN showing a net profit growth of over 190% and Banmu Huatian achieving a 495% increase in a specific product category [18][19]. - The focus of capital markets is shifting from growth speed to profit quality, indicating a more mature investment landscape where certainty is prioritized over mere growth narratives [20][21]. Group 4: Future Growth Models - The Chinese cosmetics market is expected to grow at a stable rate of 2.83% in 2025, with a shift in narrative from expansion to quality improvement, emphasizing supply-side capability upgrades [29][31]. - The new growth model is defined as "technical barriers × brand value × organizational efficiency × global layout = quality growth," contrasting with the previous model that relied on traffic and explosive product efficiency [32][39]. - Companies are increasingly focusing on technological advancements and brand building as core assets for long-term competitiveness, with an emphasis on establishing a stable profit structure [34][36]. Group 5: Global Expansion and Organizational Efficiency - Companies are looking to expand into international markets, particularly Southeast Asia and Europe, with a focus on establishing brand recognition and technical standards abroad [38][39]. - The ability to navigate through competitive pressures and establish organizational efficiency will be crucial for brands to sustain growth in a maturing market [37][39].

Core Viewpoint - The Chinese beauty industry is experiencing a significant shift as domestic brands rush to list on the Hong Kong Stock Exchange, driven by a near closure of IPO opportunities in the A-share market. This trend is not merely a celebration but signals a harsh beginning of industry differentiation and value reassessment [1][5]. Group 1: Market Dynamics - The successful listings of brands like Lin Qingxuan and the planned secondary listing of Proya highlight Hong Kong as a new haven for domestic beauty brands [1]. - The high price-to-earnings (PE) ratio of over 30 for Mao Geping is misleading, as it reflects a unique business model rather than a general trend in the domestic beauty sector [4]. - The market is expected to shift focus from the narrative of domestic brand growth to a stringent evaluation of business fundamentals [5]. Group 2: Brand Performance and Strategy - HBN and Banmu Huatian rely on traditional consumer goods models, heavily investing in marketing to drive growth, contrasting with Mao Geping's unique model that minimizes external marketing dependency [6][8]. - HBN's financials show a significant profit growth rate of 232.5% and 190.3% for 2024 and the first nine months of 2025, respectively, despite a marketing expense ratio of 57.6% [8]. - The key for HBN post-listing is to demonstrate that it can achieve higher brand premiums and customer lifetime value with the same marketing investment compared to competitors [10]. Group 3: Liquidity and Market Pressure - The liquidity risk in the Hong Kong market is severe, with top-tier companies absorbing most capital, leaving mid-tier brands vulnerable to becoming illiquid [12]. - The pressure of performance guarantees for many domestic brands in 2024-2025 may lead to unsustainable practices, risking significant stock price drops if growth slows post-2026 [13]. Group 4: Competitive Landscape - The competition in the beauty industry is evolving from ingredient concentration to structural competition, with brands needing to lower marketing costs while maintaining revenue [15]. - Unique raw materials are becoming essential for brand differentiation and valuation in the market, as seen with successful brands like Juzhibio and Lin Qingxuan [18]. - The necessity for international expansion is increasing, as domestic market growth is plateauing, making overseas markets critical for future success [20]. Group 5: Future Outlook - The Hong Kong market is becoming increasingly discerning, seeking brands that can demonstrate efficiency and long-term viability rather than just rapid growth [22][23]. - Brands that can effectively manage their desires, respect market realities, and commit to long-term strategies will be better positioned for success in the evolving landscape [23].

Core Insights - The company Lin Qingxuan, despite a high gross margin of 82.5% on its Camellia oil priced at 749 yuan, faces serious issues including false advertising, hollow R&D, and a halved valuation [2][3] - Regulatory scrutiny has intensified, with the Beijing Chaoyang District Market Supervision Bureau imposing fines for misleading claims about product efficacy [2][8] - The company is under pressure to go public due to multiple agreements with investors, leading to significant share sell-offs by founders and early investors [3][6][7] Group 1: Financial Performance and Valuation - Lin Qingxuan's valuation peaked at 3.175 billion yuan during its B round financing in 2021 but plummeted to 1.559 billion yuan by August 2024 [4][6] - The company has seen significant cash-outs by its founder and early investors, totaling 226 million yuan from August 2024 to May 2025 [3][6] - The financial data reveals a troubling reliance on a few core products, with nearly 40% of revenue coming from a single item [3][15] Group 2: Marketing vs. R&D - The marketing expenditure for 2024 was 365 million yuan, while R&D investment was only 30.4 million yuan, indicating a 12-fold disparity [10][11] - Over the years, the company has spent 760 million yuan on marketing but only 71.2 million yuan on R&D, which is less than 3% of total revenue [10][11] - The workforce is heavily skewed towards sales and marketing, with 85.2% of employees in these roles and only 64 in R&D [11] Group 3: Product Dependency and Market Challenges - The Camellia oil product accounted for 37% of total revenue in 2024, highlighting a lack of diversification in the product lineup [15] - The company has struggled to establish a foothold in lower-tier markets, with sales in these areas only reaching 60% of those in first-tier cities [15] - The franchise model has faced setbacks, with the number of franchise stores decreasing from 35 to 32, and average revenue per store significantly lower than that of direct-operated stores [15] Group 4: Regulatory and Market Pressures - The company has a history of regulatory violations, including a recent fine for false advertising regarding its anti-aging claims [8][9] - The upcoming deadline for a public listing in December 2026 poses a significant risk, as failure to meet this could result in substantial financial liabilities for the founder [19][20] - New regulations on cosmetic efficacy claims are tightening, which could further impact the company's marketing strategies [19][20]